Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veit Bücklein

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
MMW Fortschritte Der Medizin|January 17, 2023
[New treatment options for patients with Non-Hodgkin and Hodgkin lymphoma: changing treatment standards and improvements in prognosis]Veit Bücklein
Deutsche Medizinische Wochenschrift (1946)|January 20, 2026
[Flow cytometry in hematological diagnostics - step by step]Adrian Gottschlich, Marion Subklewe, Veit Bücklein
Deutsche Medizinische Wochenschrift (1946)|August 27, 2021
[Practical aspects of the application of CAR T cells and management of their toxicities]Veit Bücklein, Viktoria Blumenberg, Marion Subklewe
Deutsche Medizinische Wochenschrift (1946)|May 15, 2024
[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?]Veit Bücklein, Bastian von Tresckow, Marion Subklewe
Hematology. American Society of Hematology. Education Program|December 9, 2023
Novel immunotherapies in the treatment of AML: is there hope?Marion Subklewe, Veit Bücklein, David Sallman, et al.
Leukemia|May 6, 2021
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developmentsNaval Daver, Ahmad S Alotaibi, Veit Bücklein, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2019
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiencyClemens Küpper, Johanna Heinrich, Katharina Kamm, et al.
Oncoimmunology|September 14, 2016
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patientsVeit Bücklein, Tina Adunka, Anna N Mendler, et al.
Biomarker Research|June 10, 2022
Integrated multiomic approach for identification of novel immunotherapeutic targets in AMLThomas Köhnke, Xilong Liu, Sascha Haubner, et al.
Hemasphere|July 11, 2022
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in GermanyDaniela Skalt, Bernhard Moertl, Michael von Bergwelt-Baildon, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
MMW Fortschritte Der Medizin|January 17, 2023
[New treatment options for patients with Non-Hodgkin and Hodgkin lymphoma: changing treatment standards and improvements in prognosis]Veit Bücklein
Deutsche Medizinische Wochenschrift (1946)|January 20, 2026
[Flow cytometry in hematological diagnostics - step by step]Adrian Gottschlich, Marion Subklewe, Veit Bücklein
Deutsche Medizinische Wochenschrift (1946)|August 27, 2021
[Practical aspects of the application of CAR T cells and management of their toxicities]Veit Bücklein, Viktoria Blumenberg, Marion Subklewe
Deutsche Medizinische Wochenschrift (1946)|May 15, 2024
[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?]Veit Bücklein, Bastian von Tresckow, Marion Subklewe
Hematology. American Society of Hematology. Education Program|December 9, 2023
Novel immunotherapies in the treatment of AML: is there hope?Marion Subklewe, Veit Bücklein, David Sallman, et al.
Leukemia|May 6, 2021
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developmentsNaval Daver, Ahmad S Alotaibi, Veit Bücklein, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2019
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiencyClemens Küpper, Johanna Heinrich, Katharina Kamm, et al.
Oncoimmunology|September 14, 2016
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patientsVeit Bücklein, Tina Adunka, Anna N Mendler, et al.
Biomarker Research|June 10, 2022
Integrated multiomic approach for identification of novel immunotherapeutic targets in AMLThomas Köhnke, Xilong Liu, Sascha Haubner, et al.
Hemasphere|July 11, 2022
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in GermanyDaniela Skalt, Bernhard Moertl, Michael von Bergwelt-Baildon, et al.
Pageof 4